Field Evaluation of Two Topically Applied Insect Repellent Products Containing IR3535 Against Mosquitos in Louisiana

To determine the efficacy and duration of protection of two topically applied insect repellent products at preventing landing by mosquitos. The study will follow the EPA Product Performance Test Guidelines1. It is intended to test the products against natural populations of mosquito species of public health importance within the genera Aedes, Anopheles, and Culex, and to replace data from one site previously tested in Florida with data from a site in Louisiana with adequate landing pressure from target mosquito species of public health relevance.

Study Overview

Status

Recruiting

Conditions

Detailed Description

A single-site field setting study using healthy volunteers to test two insect repellent product formulations (lotion, and wipe) against mosquitos.

Subjects will have repellent applied to one lower limb at a standardised dose rate to account for skin area. They will then expose this area only in a field site where mosquitos are recorded landing at a rate of 5 mosquitos per 5 minute or higher. The exposure period will last five minutes and all mosquitos landing on the exposed skin will be collected using an aspirator. 5 minute exposure periods will be repeated every half hour for 14 hours for the lotion and 13 hours for the wipe, or until median CPT can be established by more than half of subjects reaching treatment failure.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kristen Healy, PhD
  • Phone Number: 225-578-7386
  • Email: khealy@lsu.edu

Study Contact Backup

Study Locations

    • Louisiana
      • Baton Rouge, Louisiana, United States, 70803
        • Recruiting
        • Louisiana State University, Department of Entomology
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able and willing to give fully informed consent;
  • Male or female;
  • Aged 18 to 55 years;
  • Consider themselves to be in good general health, and specifically:

    • Not aware of having any cardiovascular or respiratory disorder (whether active or inactive)
    • No previous anaphylaxis
    • Not aware of having a compromised immune system
  • Non-smokers or willing to refrain for 24 hours prior to and during each test;
  • Willing to undergo a mosquito attraction test (putting an arm into a cage of mosquitos)
  • Able to speak and understand English
  • Able to stand outside for periods of at least 5 minutes at a time
  • Able to understand and comply with the study procedures, including:

    • Willing to complete mosquito landing/aspirating training
    • Able to withstand exposing the lower leg to mosquitos for periods of at least 5 minutes at a time
    • Able to operate an aspirator

Exclusion Criteria:

  • Participated in any other intervention study in the previous 3 months
  • Participated in a biting insect test as part of the current study in the previous 72 hours
  • Employees, managers, and spouses of employees of the LSU and of the study Sponsor (LivFul, Inc.)
  • Students of the Study Director or any other LSU faculty/researchers involved in the study
  • Individuals suspected or known to be sensitive or allergic to, or phobic of, mosquito bites
  • Women who are pregnant, nursing or intending to become pregnant during the course of the study
  • Individuals with localized skin disorders or problems affecting the legs (such as eczema, psoriasis, or atopic dermatitis) or open cuts or scrapes
  • Individuals with known or suspected allergy or sensitivity to the test product or any of its ingredients, or any insect repellent products
  • Individuals who are not attractive to mosquitos during mosquito attractiveness test
  • Individuals who have signs or symptoms related to COVID-19, have tested positive for COVID-19 within the last 15 days, or have had contact (within 6 feet for a total of 15 minutes or more) with someone who has tested positive for COVID-19 in the last 14 days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment group
Receives a dose of repellent on the lower portion of the leg that is exposed
lotion of the repellent active ingredient IR3535
Other Names:
  • IR3535 Repellent in lotion format
wipe of the repellent active ingredient IR3535
Other Names:
  • IR3535 Repellent in wipe format
No Intervention: Control group
Does not receive a dose of repellent, but subject to similar exposure period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Median Complete Protection Time
Time Frame: 14 hours
the time for each repellent product tested that shows efficacy against mosquito bites
14 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kristen Healy, PhD, Louisiana State University Health Sciences Center in New Orleans

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 11, 2021

Primary Completion (Anticipated)

June 10, 2022

Study Completion (Anticipated)

June 10, 2022

Study Registration Dates

First Submitted

June 14, 2021

First Submitted That Met QC Criteria

May 23, 2022

First Posted (Actual)

May 27, 2022

Study Record Updates

Last Update Posted (Actual)

May 27, 2022

Last Update Submitted That Met QC Criteria

May 23, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 4370

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bites and Stings

Clinical Trials on Repellent lotion

3
Subscribe